Non-infectious uveitis is a leading cause of preventable blindness worldwide. To avert potential severe vision loss, timely diagnosis and the initiation of an effective management protocol is imperative. Systemic corticosteroids have been the gold standard and an effective first-line therapy for non-infectious uveitis, but the side effects associated with their long-term administration warrant the utilization of other therapy options. New nonsteroidal therapies have recently been approved, and other agents are currently under investigation for the treatment of non-infectious uveitis. For effective incorporation of these agents in management protocols, it is essential that their optimal use and safety profiles are understood and considered. In this Rapid Response from Chicago 2018, experts in the field provide discussion on the need for nonsteroidal options for the long-term management of non-infectious uveitis and evaluate the latest clinical evidence regarding new and emerging nonsteroidal options for long-term treatment of the disease.
Abstract: Preservatives used in topical glaucoma medications have a plethora of well-described toxic effects on the ocular surface. Such ocular toxicity is manifest clinically as ocular surface disease (OSD) and has been confirmed in epidemiologic, prospective clinical trials and studies in which patients are switched from preservative-added to preservative-free topical therapy. Such toxicity has implications not only for tolerability, but also for adherence and persistence with therapy that is known to be poor in glaucoma. Glaucoma medication is now widely avail- able in preservative-free formulations, and the question arises as to which patients should receive preservative-free glaucoma therapy in preference to preservative-added medication. A case can be made for several subpopulations of patients who might particularly benefit from preservative-free medication: patients with existing OSD, older patients, younger adult patients, female patients, pediatric and juvenile patients, patients who work in air-conditioned environ- ments or who use electronic screens frequently, patients with medical risk factors for OSD, patients in whom trabecular surgery may become indicated in the future, contact lens users, perhaps patients with Asian ethnicity and patients with severe or treatment-refractory glaucoma. Whilst arguments could be made for selecting patients for preservative-free medication on the basis of their existing risk of OSD, collectively, these patients form a significant proportion of the glaucoma patient population as a whole and, in the absence of any cost premium or positive indication for preservative-added medication, preservative-free glaucoma medication for all patients seems an appropriate strategy.
Премия «Золотой лорнет» за пять лет развития стала традиционным местом испытания для участников рынка медицинской оптики: товаров и услуг, оборудования и расходных материалов, очковых и контактных линз, солнцезащитных очков и медицинских оправ, дистрибуторских и розничных сетей, а также магазинов оптики в России.
Конкурс содействует созданию и развитию Программы сохранения здоровья зрения населения России как важнейшей задачи оптической индустрии в целом; консолидирует и развивает национальный рынок оптических товаров и услуг, выявляет и поддерживает лидеров оптического рынка страны, повышает знание и формирует благоприятное отношение конечных потребителей к офтальмологии и оптике, и, в целом, стимулирует развитие деловой активности отечественного предпринимательства.
Purpose: Tetracaine is one of the most common eye drops that are used for analgesia in clinical practice. However, it causes ocular burning sensation when instilled. This study aimed to compare the effects of the cold and room temperature tetracaine on burning sensation.
Patients and methods: We conducted a prospective, double-blinded, randomized controlled trial at the ophthalmology outpatient clinic, Phramongkutklao Hospital during January 2016–February 2017. In this study, 424 consecutive patients (those with a history of keratopathy or neuropathy were excluded) who received dilated fundus examination were randomized to receive cold tetracaine (4°C) in one eye and room temperature tetracaine (22.5°C) in the other eye. Each patient was asked to answer the questionnaire on the severity of burning sensation using 100 mm visual analog scale.
Results: Patients reported less burning sensation on the eye that received cold tetracaine (visual analog scale 20.50±18.8 vs 22.70±20 mm; P=0.025). In the subgroup analysis, young patients (≤40 years old), female subjects, patients who received tetracaine for the first-time and those who had no previous ocular surgery reported more benefit from cold tetracaine. The subgroup of patients who had normal corneal sensation, identified by using a Cochet–Bonnet esthesiometer, also showed greater benefit from cold tetracaine compared to those with impaired corneal sensation.
Conclusion: Cold tetracaine caused less burning sensation than room temperature solution. Its benefit was greater in the subgroup of patients who reported more severe burning sensation. We recommend using cold tetracaine in routine practice, especially in those who are anticipated to have this common side effect.
Because glaucoma typically begins by affecting the far periphery of the vision, most patients are unaware that they have the disease until it progresses and destroys central vision. As a result, nearly half of those with glaucoma remain undiagnosed, and 50% have advanced disease at the time of diagnosis. Since glaucoma-related vision loss is permanent and treatment can slow progression and prevent blindness in 90% of cases, regular screening of at-risk patients to detect and treat glaucoma early is both worthwhile and recommended.
Samuel F Passi,* Atalie C Thompson,* Preeya K Gupta
Department of Ophthalmology, Duke University Eye Center, Durham, NC, USA
*These authors contributed equally to this work
Purpose: To compare the agreement and efficiency of a swept source-optical coherence tomography biometer, IOLMaster 700 (IOLM700), and a low-coherence optical reflectometry biometer, LENSTAR LS 900 (LS900), when acquiring biometry measurements during cataract evaluation.
Retina World Congress is a non-profit organization dedicated to uniting international professionals to foster dialogue and to generate consensus about retinal diseases, emerging technologies and treatments, best practices and clinical research. Our biennial meeting is our main initiative and has brought together 150 faculty and 1,000 attendees from 32 U.S. states, 74 countries and 39 retina societies from around the globe. We unite again in 2019 to share research, innovations and ideas with a growing audience... and we want you to be a part of it!
OCT imaging has become an indispensable tool in uveitis practice. It is the standard diagnostic technique in the detection, monitoring of treatment, and determination of prognosis in uveitic macular edema (ME) as well as in other macular and extramacular inflammatory changes. OCT technology has evolved in the last
2 decades from time domain OCT (TD-OCT) to spectral domain OCT (SD-OCT) and recently to the enhanced-depth imaging OCT (EDI-OCT) and Topcon’s Swept Source OCT (SS-OCT).1
Lausanne, Switzerland, October 3rd 2018, Sensimed is pleased to announce the registration of the SENSIMED Triggerfish® sensor and monitoring system as a medical device in Japan.
The Japanese partner and distributor of Sensimed, SEED Co., Ltd., has obtained the approval from the Ministry of Health, Labour and Welfare. The device will be available for sale towards the end of 2018.
Abstract Deadline: September 7, 2018
Abstract Notification: September 26, 2018
Early-bird Registration ends: September 29, 2018
Visa Request Deadline: October 26, 2018
Regular Registration ends: October 31, 2018
Wetlab and Workshop Registration ends: November 9, 2018
Сайт основан 20 декабря 2000 года
Авторские права на дизайн и всю информацию веб-сайта www.eyenews.ru (www.glaucomanews.ru www.corneanews.ru, www.cataractanews.ruwww.retinanews.ru www.айньюс.рф www.hrtclubrussia.ru), а также на подбор и расположение материалов принадлежат учредителю и редакции вышеуказаных порталов. Использование материалов сайтов разрешено только с письменного разрешения учредителя и редакции вышеуказанных сайтов. Воспроизведение фотографий, статей и новостей, абстрактов и прочего контента любым способом без письменного разрешения запрещено и влечет ответственность, предусмотренную законодательством о защите авторских прав. Запрещается автоматизированное извлечение информации сайта любыми сервисами без официального разрешения учредителя либо редакции сайтов. При цитировании материалов ссылка наwww.eyenews.ru и другие вышеуказанные сайты обязательна.